0.93
0.93 (0%)
As of Mar 25, 2024
Homology Medicines, Inc. [FIXX]
Source:
Company Overview
Q32 Bio Inc is a clinical stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction.
| Country | United States |
| Headquarters | bedford, massachusetts |
| Phone Number | (781) 301-7277 |
| Industry | manufacturing |
| CEO | Arthur Tzianabos |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-66.1 |
| Net Income | $-47.7 |
| Net Cash | $47.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -68.5% |
| Profit as % of Stockholder Equity | -841.1% |
Management Effectiveness
| Return on Equity | -841.1% |
| Return on Assets | -51.7% |
| Turnover Ratio | |
| EBITA | $-66.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $92.3 |
| Total Liabilities | $86.7 |
| Operating Cash Flow | $-67.7 |
| Investing Cash Flow | $19.9 |
| Financing Cash Flow | $95.1 |
